Uniphar | Clinical merges with BMclinical to strengthen global clinical trial services
February 16, 2026 |
Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and biotech companies worldwide.
As part of Uniphar’s global platform supporting the full product lifecycle – from early clinical development through to commercialization and beyond – Uniphar | Clinical leverages scalable infrastructure and deep expertise to provide bespoke packaging, labeling, storage and distribution solutions, while BMclinical brings extensive experience in comparator sourcing and clinical trial supply.
The combined Uniphar | Clinical offering will streamline clinical supply chains, minimize execution risk, and ensure continuity from study initiation through to completion, helping sponsors deliver therapies to patients faster. In addition, this broader offering enhances Uniphar’s ability to support partners across every stage of development, capitalizing on the scale and efficiency of a unified global sourcing model.
“As global trials become more complex, sponsors increasingly value partners who can combine scale with specialist expertise,” said Dermot Ryan, Chief Operating Officer at Uniphar. “By aligning BMclinical’s sourcing capabilities with Uniphar | Clinical’s integrated platform, we provide a comprehensive suite of clinical services based on agility and dependability that set a new standard for our partners and ultimately accelerate patient access to critical therapies.”
Integrated services
Building on Uniphar | Clinical’s and BMclinical’s combined expertise, the new partnership offers a comprehensive range of integrated services designed to support every stage of clinical trial supply, including: commercial drug supply capability including global sourcing of comparators; packaging and labeling services spanning both primary and secondary clinical packaging; global storage and distribution capabilities, including compliant facilities equipped with real-time temperature monitoring; and overage management solutions.
With strategically located GMP- and GDP-compliant flagship facilities in Lelystad, the Netherlands, and Raleigh, North Carolina, alongside a distribution footprint spanning Europe, North America, APAC, and MENA, the partnership is positioned to deliver temperature-sensitive clinical materials reliably, wherever trials are underway.
Shanelle Austin-Mehta, Director of Uniphar | Clinical said: “Bringing the expertise of Uniphar | Clinical and BMclinical together creates an unparalleled service offering to the pharmaceutical and biotech industry – one designed to anticipate challenges and provide the reliability sponsors need to keep studies on track.”
For more information, visit https://unipharclinical.com/
This content was provided by Uniphar
Company Details
Latest Content from Uniphar
Uniphar | Clinical merges with BMclinical to strengthen global clinical trial services
Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and biotech companies worldwide. As part of Uniphar’s global platform supporting...
Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
- New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand. - Mike Ebhardt is appointed President of Uniphar Pharma...
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...
Navigating the complexities of launch preparation for Cell and Gene Therapy
Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...
Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering
Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...
Uniphar Secures 10th Cell and Gene Therapy Project
[Dublin, April 17th 2025] Uniphar, a global leader in pharmaceutical and medtech solutions has announced the launch of its 10th cell and gene therapy (CGT) project. The milestone reinforces Uniphar’s...
- 1
- 2